Skip to main content

Fisher Acquires BioImage in Bid to Grow High-Content Cell-based Assay Play

NEW YORK, April 26 (GenomeWeb News) - Fisher Biosciences has acquired BioImage for an undisclosed amount in an effort to expand its high-content screening and analysis reagent play, the company said today.


BioImage plays in the high-content pathway-analysis market. Its Redistribution technology monitors protein translocation within a cell.


Fisher said BioImage, based in Copenhagen, Denmark, complements its Cellomics business, which sells automated imaging instruments, BioApplication image-analysis software, high content informatics software, and HitKit HCS reagent kits.


Fisher will continue BioImage's operations in Copenhagen.


Additional details were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.